smartPearls® for dermal bioavailability enhancement – long-term stabilization of suspensions by viscoelasticity
Publication date: Available online 8 March 2019Source: International Journal of PharmaceuticsAuthor(s): David Hespeler, Daniel Knoth, M. Cornelia Keck, H. Rainer Müller, Sung Min PyoAbstractsmartPearls® are a novel dermal delivery system based on mesoporous (pores 2-50 nm) particles, developed in 2014. Their pores can be loaded with active which is long-term stabilized in its amorphous state. The increased saturation solubility by the amorphous state leads to an increased dermal bioavailability of poorly soluble actives. To avoid sedimentation of the porous particles (3-50 µm) in dermal formulations, viscoelastic gels were developed usingι–carrageenan, polyacrylate and the viscoelastic Kühne salad dressing as a reference from food industry. Silica particles (company Grace/US, 50 and 150 µm) were loaded into the gels and long-term stability was assessed by a VIS sedimentation test. Furthermore, the gels were characterized by analytical centrifugation (LUMiSizer®) to assess the critical rpm/g values, allowing to order them after their absolute viscoelastic stabilizing ability. Characterization was complemented by rotation rheology, amplitude sweep and a frequency sweep analysis for the determination of elastic and viscous moduli Ǵ and Ǵ́ at varying conditions. Based on the throughout characterization, polymers can be selected to sufficiently stabilize dermal formulations even with large sized smartPearls® – the prerequisite ...
ConclusionsCompressed sensing reduced the acquisition time of conventional MR imaging of the ankle by 20% without decreasing diagnostic image quality, SNR and CNR.
Hilary Nickols, MD, PhDFrom time to time, I feature neuropathologists who exhibit talents beyond the strict confines of neuropathology. For example, I recently features the inimitableMark Cohen and his prodigious classical guitar skills. I discovered another neuropathologist/artist during the recent annual meeting of the American Association of Neuropathologists: Hilary Nickols, MD, PhD, of Norton Healthcare in Louisville, Kentucky. Dr. Nickols shared with me her detailed drawing of a craniotomy surgical field which she recently witnessed during a visit to the operating room.The scene in the operating room, including ...
Conclusion. This kind of procedure should be kept in the therapeutic armament in the current setting of costly targeted systemic treatments of spondyloarthritis. However, definition of a clear position in the treatment strategy needs further well conducted studies.
ConclusionsPamidronate is a safe and efficient method of CRMO therapy, particularly in cases refractory to NSAIDs treatment. Treatment with pamidronate provides both symptomatic relief as well as normalisation of bone morphology.
Publication date: Available online 16 June 2019Source: Joint Bone SpineAuthor(s): Pierre Letellier, Florian Bailly, Marina Assadourian, Antoine Potel, Violaine Foltz, Sophia Ascione, Laetitia Morardet, Myrianne Le Ralle, Bruno Fautrel, Arnaud Dupeyron, Nada Ibrahim-Nasser, Isabelle Griffoul-Espitalier, Bernard Duplan, Johann Beaudreuil, Laure Gossec
Inducing seizures with cortical stimulation accurately identifies the target area for resection and significantly reduces hospital stays, a new study shows.Medscape Medical News
Cochlear Limited has received U.S. Food and Drug Administration (FDA) clearance...Read more on AuntMinnie.comRelated Reading: FDA OKs new MRI-conditional cochlear implant
Pfizer has agreed to buy Array Biopharma in a $10.64 billion cash deal.
As researchers continue to hunt for ways to treat or prevent Alzheimer ’s disease, one study has shown promise in slowing the progression of the disease.
The company started with fewer than 20 employees in 2017.